Three Gold Standards awarded for partnership work in patient advocacy and communications
News
Cell and Gene Therapy Catapult forms consortium of over 20 organisations
Consortium will assess multiple process analytical technologies used in the cell and gene therapy industry
Bayer subsidiary doses first patient with Parkinson’s disease cell therapy
German pharma company announces progress in its ‘two-pronged’ cell and gene therapy approach to Parkinson’s disease
Opdivo combos show OS benefit in advanced oesophageal cancer
Opdivo plus chemotherapy or Yervoy demonstrated overall survival benefit in PD-L1-positive and all-randomised populations
Astellas’ Xtandi bags NICE approval in prostate cancer
Oral androgen receptor signalling inhibitor now approved to treat metastatic hormone-sensitive prostate cancer
£3m worth of illegally sold meds and devices seized in UK
Under Operation Pangea, officers were also able to shut down or block 113,000 illegally operating websites
Amicus’ Pompe disease therapy joins early access scheme
The MHRA has issued an EAMS scientific opinion opening the door to use of cipaglucosidase alfa with miglustat in eligible patients with Pompe disease
No survival benefit from aspirin in COVID-19 patients
The NIHR-supported RECOVERY trial found that the anti-inflammatory drug does not improve survival for hospitalised patients with COVID-19
Gov’t announces delay to GP data extraction scheme
The programme will now roll out early September to ensure patients have more time to consider whether to opt out of sharing their data
Entry closing next Friday for CROY 2021
Entry for the 2021 Clinical Researcher of the Year – The Americas will be closing next Friday the 18th of June.
New research identifies single biomarker that can indicate underlying neurodegeneration
Blood test can be used to identify the presence of a protein that can reveal underlying neurodegeneration
SMC backs five new medicines for NHS use
Servier’s Lonsurf and AstraZeneca’s Calquence are among the positive decisions
NICE recommends Tecentriq for first-line NSCLC
Tecentriq is indicated for adults with metastatic NSCLC if their tumours have PD-L1 expression on at least 50% of tumour cells or 10% of tumour-infiltrating immune cells
Biogen, Eisai’s Alzheimer’s drug aducanumab makes history with US approval
First new treatment approved for Alzheimer’s disease in over a decade
Tickets now on sale for INTCR 2021
Individual tickets or tables are now available for the 2021 International Clinical Researcher of the Year awards.
